Alzheimer's disease (AD) is the most prevalent form of age-related dementia in the world,
and its main pathological features consist of amyloid-β (Aβ) plaque deposits and …

Alzheimer's disease (AD), is a progressive neurodegenerative disease that affects behavior,
thinking, learning, and memory in elderly individuals. AD occurs in two forms, early onset …

Immunotherapy against amyloid-beta (Aβ) is a promising option for the treatment of
Alzheimer's disease (AD). Aβ exists as various species, including monomers, oligomers …

The formation of amyloid fibrils is a general class of protein self-assembly behaviour, which
is associated with both functional biology and the development of a number of disorders …

Aducanumab is a monoclonal antibody selective for amyloid β (Aβ) aggregates. In June
2021, aducanumab became the first drug underlying the pathophysiology of Alzheimer's …

Recent Aβ-immunotherapy trials have yielded the first clear evidence that removing
aggregated Aβ from the brains of symptomatic patients can slow the progression of …

Condensed states of proteins, including liquid-like membraneless organelles and solid-like
aggregates, contribute in fundamental ways to the organisation and function of the cell …

Disrupted protein folding or decreased protein stability can lead to the accumulation of
(partially) un‐or misfolded proteins, which ultimately cause the formation of protein …

A large body of clinical and nonclinical evidence supports the role of neurotoxic soluble beta
amyloid (amyloid, Aβ) oligomers as upstream pathogenic drivers of Alzheimer's disease …

Conspectus Metal ions have been identified as key factors modulating the aggregation of
amyloid-β peptide (Aβ) implicated in Alzheimer's disease (AD). The presence of elevated …